InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.067 0.007 (11.67%)+
Announcement
Release
12 Jun 2026 9:07AM
Price at Release
$0.060
Full Release
download
Summary
Neurizon Therapeutics Limited announced that they have surpassed the 50% dosing milestone in Regimen I of the HEALEY ALS Platform Trial, which evaluates the NUZ-001 treatment for ALS. The trial's Regimen I was recently expanded from 160 to 240 participants, and as of 9 June 2026, 129 participants have been dosed across 78 clinical sites in the United States. This progress highlights the trial's operational efficiency and strong engagement from the ALS community. Neurizon aims to complete the last participant dosing by Q2 CY2027 and expects to release topline results by early Q3 CY2027.
Key Points
  • 129 of 240 participants dosed in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001
  • Regimen I expansion from 160 to 240 participants
  • 167 participants assigned to Regimen I as of 9 June 2026
  • 78 clinical trial sites activated across the United States
  • Neurizon positioned for last participant dosing in Q2 CY2027 and topline results in early Q3 CY2027
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.